{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=22&sponsor=Bristol-Myers+Squibb", "query": { "sponsor": "Bristol-Myers Squibb", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 2034, "total_pages": 204, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=23&sponsor=Bristol-Myers+Squibb&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=21&sponsor=Bristol-Myers+Squibb&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T13:27:49.560Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06094842", "title": "Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Carcinoma", "Prostate Small Cell Neuroendocrine Carcinoma", "Stage III Prostate Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Bridge Therapy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "T-cell Receptor-engineered T-cells", "type": "BIOLOGICAL" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2025-04-15", "completion_date": "2028-03-15", "has_results": false, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-10-14T13:27:49.560Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06094842" }, { "nct_id": "NCT05050305", "title": "Marizomib Central Nervous System (CNS)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse", "Multiple Myeloma, Refractory" ], "interventions": [ { "name": "Marizomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-03", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-10-14T13:27:49.560Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05050305" }, { "nct_id": "NCT01844505", "title": "Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable or Metastatic Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Placebo for Nivolumab", "type": "BIOLOGICAL" }, { "name": "Placebo for Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 945, "start_date": "2013-06-11", "completion_date": "2024-04-19", "has_results": true, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-10-14T13:27:49.560Z", "location_count": 46, "location_summary": "Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 35 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844505" }, { "nct_id": "NCT00083720", "title": "Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms", "Metastases", "Neoplasm" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2004-10", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2011-05-25", "last_synced_at": "2026-10-14T13:27:49.560Z", "location_count": 23, "location_summary": "Campbell, California • Los Angeles, California • Soquel, California + 20 more", "locations": [ { "city": "Campbell", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Soquel", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083720" }, { "nct_id": "NCT00914641", "title": "Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Thrombosis" ], "interventions": [ { "name": "Apixaban IR", "type": "DRUG" }, { "name": "Apixaban MR1", "type": "DRUG" }, { "name": "Apixaban MR2", "type": "DRUG" }, { "name": "Apixaban MR3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 16, "start_date": "2009-06", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2009-08-25", "last_synced_at": "2026-10-14T13:27:49.560Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00914641" }, { "nct_id": "NCT02863523", "title": "COMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 2 Diabetes Mellitus", "Diabetes-related Distress", "Depression" ], "interventions": [ { "name": "Integrated Behavioral Care", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "East Carolina University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "19 Years to 75 Years" }, "enrollment_count": 139, "start_date": "2014-09", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2023-12-08", "last_synced_at": "2026-10-14T13:27:49.560Z", "location_count": 1, "location_summary": "Greenville, North Carolina", "locations": [ { "city": "Greenville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02863523" }, { "nct_id": "NCT03316586", "title": "A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2017-11-30", "completion_date": "2019-08-30", "has_results": true, "last_update_posted_date": "2021-12-28", "last_synced_at": "2026-10-14T13:27:49.560Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03316586" }, { "nct_id": "NCT03583086", "title": "Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Thymic Carcinoma", "Non-small Cell Lung Cancer", "Refractory Thoracic Tumors", "Small-Cell Lung Cancer" ], "interventions": [ { "name": "Vorolanib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2018-07-10", "completion_date": "2024-04-27", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-10-14T13:27:49.560Z", "location_count": 7, "location_summary": "Palo Alto, California • Atlanta, Georgia • Chicago, Illinois + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03583086" }, { "nct_id": "NCT03635983", "title": "A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "NKTR-214", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 783, "start_date": "2018-09-21", "completion_date": "2024-03-19", "has_results": true, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-10-14T13:27:49.560Z", "location_count": 24, "location_summary": "Tucson, Arizona • La Jolla, California • Stanford, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635983" }, { "nct_id": "NCT00546741", "title": "Drug Interaction With Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Male and Female Subjects" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Dapagliflozin + Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 18, "start_date": "2007-11", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2016-12-20", "last_synced_at": "2026-10-14T13:27:49.560Z", "location_count": 1, "location_summary": "Hamilton, New Jersey", "locations": [ { "city": "Hamilton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00546741" } ] }